Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti–Insulin-Like Growth Factor Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-I (IGF-I), IGF-II, and insulin have all been implicated in regulating several aspects of the malignant phenotype via the type I IGF receptor (IGF1R) and insulin receptor (IR). We have previously shown that a chimeric single-chain antibody against IGF1R (scFv-Fc) and a murine antibody EM164 down-regulate IGF1R, making breast cancer cells unresponsive to IGF-I. To determine if IR signaling is affected, we examined regulation of IR in MCF-7 cells after exposure to these antibodies. Surprisingly, both scFv-Fc and EM164 resulted in decreased levels of IR in vitro and in vivo despite their lack of reactivity against IR. Twenty-four-hour pretreatment with EM164 also inhibited insulin-mediated phosphorylation of IR and insulin-stimulated proliferation of MCF-7 cells. Neither scFv-Fc nor EM164 caused down-regulation of IR in cells that express very low levels of IGF1R or no IGF1R. Expression of IGF1R was required for IR down-regulation, which was specific as neither antibody caused down-regulation of β1 integrin or epidermal growth factor receptor. Reagents that disrupt lipid rafts inhibited IR down-regulation by the antibodies, suggesting that IR in close physical proximity to IGF1R in lipid rafts was being endocytosed. Our data show that down-regulation of IR by monoclonal antibodies against IGF1R requires the coexpression of IGF1R and may be due to endocytosis of hybrid IR/IGF1R or holo-IR. Thus, antibodies against IGF1R provide inhibition of both IGF and insulin signaling in cancer cells. (Cancer Res 2006; 66(4): 2391-402)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567 · cited 1×
“G protein a inhibitory subunit (Gai2) was used as a loading control and marker for lipid rafts (36) and was present only in lanes 4 to 6, which represent the raft fraction (Fig.”
MethodElevated insulin receptor content in human breast cancer
Papa, V, Pezzino, V, Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., & Vigneri, R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114868 · Cited by 338 · cited 1×
“normal breast tissue and fibroadenoma specimens (22).”
Laron, Z. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6255 · Cited by 96
Cited by
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
The Type 1 Insulin-Like Growth Factor Receptor Pathway
Chitnis, M. M., Yuen, J. S. P., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4879 · Cited by 445
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Clemmons, D. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2359 · Cited by 340
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Sachdev, D., & Yee, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0080 · Cited by 320
Self-citationDisrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
Sachdev, D., & Yee, D. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0080 · Cited by 314
Self-citation
Metadata
- Authors
- Sachdev, D., Singh, R., Fujita-Yamaguchi, Y., & Yee, D.
- Venue
- Cancer Research
- Published
- 2006-02-15
- Volume
- 66
- Issue
- 4
- Pages
- 2391-2402
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2120310702
- Cited by
- 117
- References
- 3
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti–Insulin-Like Growth Factor Therapy in Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3126
- The paper
- Sachdev, D., Singh, R., Fujita-Yamaguchi, Y., & Yee, D. (2006). Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti–Insulin-Like Growth Factor Therapy in Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.